Korsana Biosciences closed at $31.66 on Nov 2, up 5.04%, 14.9% below its highest close since Sep 11. Volume of 197.5K shares was 1.32× its 20-day average (above normal).
Split-adjusted performance: +3.8% over one month.
Short interest was 23.8K shares at the Oct 15 settlement, up 106.1% from the prior report (1.0% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.1%, revenue growth +6.4%, net margin −36.2%, P/E 15.8×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| KRSAKorsana Biosciences | $31.66 | +5.04% | — | — | — | — | $1.44B | |
| ETONEton Pharmaceutcials | $50.81 | −2.63% | +68.5% | +98.6% | 30.8% | 114.5 | $1.45B | Compare |
| PCRXPacira BioSciences | $36.40 | +0.03% | +47.4% | +6.2% | 2.4% | 99.2 | $1.45B | Compare |
| TYRATyra Biosciences | $21.33 | +1.23% | −39.3% | — | — | — | $1.47B | Compare |
| RAPPRapport Therapeutics | $25.13 | +0.32% | −29.3% | — | — | — | $1.42B | Compare |
| OCULOcular Therapeutix | $6.73 | −3.44% | −31.1% | +0.1% | −584.5% | — | $1.48B | Compare |
| ANABAnaptysBio | $46.91 | −2.84% | −32.8% | −8.0% | −206.9% | — | $1.40B | Compare |
| MLYSMineralys Therapeutics | $15.55 | −14.47% | −47.6% | — | — | — | $1.37B | Compare |
| INVAInnoviva | $21.02 | −0.94% | −8.6% | +19.3% | −69.8% | 4.3 | $1.52B | Compare |
No recent articles focused on Korsana Biosciences. 1 articles mention it in passing.
Korsana Biosciences Inc is a biopharmaceutical company developing therapeutics to treat neurodegenerative diseases beginning with Alzheimer's disease (AD. The company's flagship product candidate, KRSA-028, is an anti-amyloid beta antibody that combines the proprietary Therapeutic Targeting (THETA) platform with well-validated aspects from other anti-Ab products that have achieved regulatory approval or are in late-stage clinical trials.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
